Core Viewpoint - Jiutian Pharmaceutical (300705) plans to acquire a 10% stake in Nona Pharmaceutical, increasing its ownership from 60% to 70% by using its own funds of 46.5845 million yuan [1] Group 1 - The acquisition will enhance Jiutian Pharmaceutical's control over Nona Pharmaceutical [1] - The transaction reflects Jiutian Pharmaceutical's strategy to strengthen its investment in the pharmaceutical sector [1]

Core Viewpoint - Jiutian Pharmaceutical plans to acquire an additional 10% stake in Hunan Nona Pharmaceutical Technology Co., Ltd. for 46.5845 million yuan to strengthen its control and strategic positioning in the biopharmaceutical sector [1] Group 1: Acquisition Details - The acquisition will increase Jiutian Pharmaceutical's ownership in Nona Pharmaceutical from 60% to 70% [1] - Nona Pharmaceutical will continue to be a subsidiary of Jiutian Pharmaceutical and will remain within the consolidated financial statements [1] Group 2: Strategic Implications - The acquisition is aimed at enhancing control over Nona Pharmaceutical, facilitating resource integration within the industry chain [1] - This move aligns with Jiutian Pharmaceutical's long-term development strategy to boost its competitiveness in the biopharmaceutical field [1]

Core Viewpoint - The company plans to use its own funds of 46.5845 million yuan to acquire a 10% stake in Nona Pharmaceutical held by Shangshan Hongren, increasing its ownership in Nona Pharmaceutical from 60% to 70% [1] Group 1: Company Strategy - The transaction aims to consolidate the company's controlling position in Nona Pharmaceutical [1] - This move is part of the company's strategy to deepen its layout in the biopharmaceutical sector [1]

智通财经APP讯，九典制药(300705.SZ)公告，公司拟使用自有资金4658.45万元，收购上善弘仁持有的 诺纳医药10%股权。交易完成后，公司对诺纳医药的持股比例将由60%提升至70%，诺纳医药仍为公司 控股子公司。相关事项旨在巩固对诺纳医药控股地位，进一步深化公司在生物医药领域的战略布局。 ...

Group 1 - The company Jiutian Pharmaceutical (SZ 300705) announced that its 15th meeting of the 4th board of directors was held on November 17, 2025, to review documents including proposals for external investments [1] - For the first half of 2025, Jiutian Pharmaceutical's revenue composition was as follows: 82.47% from pharmaceutical preparations, 7.65% from raw materials, 6.03% from pharmaceutical excipients, 3.16% from plant extracts and others, and 0.63% from technology transfer and services [1] - As of the report date, Jiutian Pharmaceutical's market capitalization was 8.4 billion yuan [1]

关于对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 1、基本注册信息 注册地址：海南省三亚市海棠区亚太金融小镇南 6 号楼 2 区 22-02-119 号 企业名称：海南上善弘仁私募创业投资基金合伙企业（有限合伙） 企业类型：有限合伙企业 经营范围：一般项目：以私募基金从事股权投资、投资管理、资产管理等活 动（须在中国证券投资基金业协会完成登记备案后方可从事经营活动）（除许可 业务外，可自主依法经营法律法规非禁止或限制的项目） 统一社会信用代码：91460000MA7KCPQR8L 2、合伙人信息 成立时间：2022 年 03 月 18 日 一、对外投资概述 湖南九典制药股份有限公司（以下简称"公司"或"九典制药"）为巩固对 湖南诺纳医药科技有限公司（以下简称"诺纳医药"）的控股地位，进一步深化 公司在生物医药领域的战略布局，拟使用 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 具体内容详见公司在巨潮资讯网上披露的《关于对外投资的公告》。 表决结果：7 票同意，0 票回避，0 票反对，0 票弃权。 三、备查文件 湖南九典制药股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖南九典制药股份有限公司（以下简称"公司"）第四届董事会第十五次会 议于 2025 年 11 月 17 日在公司 921 会议室以现场结合通讯会议的方式召开，会 议通知已于 2025 年 11 月 14 日以邮件方式送达。本次会议应出席的董事 7 人， 实际出席的董事 7 人（其中以通讯方式出席会议的董事有：杨洋先生、范朋云 先生、阳秋林女士、周从山先生、向静女士），全体监事、高级管理人员列席了 会议，会议由董事长朱志宏先生召集并主持。本次会议的召开符合有关法律、 法规和《公司章程》的规定，形成的决议合法有效。 ...

资料显示，湖南九典制药股份有限公司位于湖南省长沙高新开发区麓天路28号金瑞麓谷科技园A1栋， 成立日期2001年1月19日，上市日期2017年10月10日，公司主营业务涉及医药产品的研发、生产和销 售。主营业务收入构成为：药品制剂82.47%，原料药7.65%，药用辅料6.03%，提取物及其他3.16%，技 术转让及服务0.63%，其他(补充)0.05%。 九典制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：中药、熊去氧胆酸、医 药电商、创新药、原料药等。 11月17日，九典制药盘中下跌2.05%，截至13:45，报16.76元/股，成交1.27亿元，换手率2.04%，总市值 83.84亿元。 资金流向方面，主力资金净流出1540.57万元，特大单买入0.00元，占比0.00%，卖出538.52万元，占比 4.23%；大单买入1488.27万元，占比11.68%，卖出2490.32万元，占比19.54%。 九典制药今年以来股价跌4.99%，近5个交易日跌0.30%，近20日涨0.24%，近60日跌4.99%。 分红方面，九典制药A股上市后累计派现4.50亿元。近三年，累计派现3.46亿元。 ...

11月14日，九典制药盘中上涨2.06%，截至10:45，报17.30元/股，成交1.27亿元，换手率2.01%，总市值 86.54亿元。 资金流向方面，主力资金净流入776.50万元，特大单买入354.53万元，占比2.79%，卖出130.42万元，占 比1.03%；大单买入2502.27万元，占比19.68%，卖出1949.88万元，占比15.34%。 九典制药今年以来股价跌1.93%，近5个交易日涨4.85%，近20日涨2.85%，近60日跌0.35%。 资料显示，湖南九典制药股份有限公司位于湖南省长沙高新开发区麓天路28号金瑞麓谷科技园A1栋， 成立日期2001年1月19日，上市日期2017年10月10日，公司主营业务涉及医药产品的研发、生产和销 售。主营业务收入构成为：药品制剂82.47%，原料药7.65%，药用辅料6.03%，提取物及其他3.16%，技 术转让及服务0.63%，其他(补充)0.05%。 九典制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：熊去氧胆酸、中药、创 新药、医药电商、原料药等。 截至9月30日，九典制药股东户数3.47万，较上期减少10.37%；人均流通 ...

Core Insights - The healthcare innovation sector is showing positive momentum, with the China Securities Medicine and Medical Device Innovation Index (931484) rising by 0.31% as of November 14, 2025, and several key stocks, including Sanofi and Ganli Pharmaceutical, experiencing significant gains [1] Group 1: Market Performance - The China Securities Medicine and Medical Device Innovation Index has seen a 0.31% increase, with notable stock performances: Sanofi up 4.64%, Ganli Pharmaceutical up 3.28%, and Jiutian Pharmaceutical up 1.83% [1] - The Medical Innovation ETF (516820) has also risen by 0.26%, marking its third consecutive increase [1] Group 2: Clinical Developments - AstraZeneca announced successful Phase III clinical trials for Baxdrostat, which significantly reduced 24-hour average systolic blood pressure in patients with resistant hypertension over 12 weeks, indicating a new treatment pathway for hypertension [1] Group 3: Industry Trends - According to Dongfang Caifu Securities, the pharmaceutical industry showed improvement in Q3 2025, with the medical device sector experiencing a turning point, achieving positive year-on-year revenue growth and a notable narrowing of net profit declines [1] - The CXO sector performed exceptionally well in the first three quarters of 2025, with medical R&D outsourcing revenue increasing by 12.2% and net profit rising by 56.8%, particularly in ADC CDMO and peptide CDMO fields [2] - The index reflects the performance of 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors, with the top ten stocks accounting for 64.12% of the index [2]